http://orcid.org/0000-0001-7939-7204
Citations (34)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Rosanne W Meijboom, Liese Barbier, Louise C Druedahl, Kati Sarnola, Hanna M Tolonen, Helga Gardarsdottir, Toine C G Egberts & Thijs J Giezen. (2023) Recommendations on TNFα inhibitor biosimilar use in clinical practice: a comparison of European gastroenterology IBD guidance. Expert Opinion on Biological Therapy 23:8, pages 801-817.
Read now
Read now
Hemlata Chhabra, Morgane C Mouslim, Smita Kashiramka & Anurag S Rathore. (2022) Dynamics of biosimilar uptake in emerging markets. Expert Opinion on Biological Therapy 22:6, pages 679-688.
Read now
Read now
Steven Simoens & Raymond Cheung. (2020) Tendering and biosimilars: what role for value-added services?. Journal of Market Access & Health Policy 8:1.
Read now
Read now
Ahmad Albshesh & Shomron Ben-Horin. (2019) CT-P13: a review on a biosimilar to infliximab in the treatment of inflammatory bowel disease. Expert Opinion on Biological Therapy 19:10, pages 971-978.
Read now
Read now
András Inotai, Tamás Ágh, Alexei Willem Karpenko, Antal Zemplényi & Zoltán Kaló. (2019) Behind the subcutaneous trastuzumab hype: evaluation of benefits and their transferability to Central Eastern European countries. Expert Review of Pharmacoeconomics & Outcomes Research 19:2, pages 105-113.
Read now
Read now
Articles from other publishers (29)
Evelien Moorkens, Teresa Barcina Lacosta, Dalia Dawoud, András Inotai, Manthan Janodia, Chia Jie Tan, Ka Keat Lim, Nishtha Khatri, Catarina Lopes Pereira & Steven Simoens. (2023) A Systematic Literature Review of Gaps and Challenges in Value Assessment of Biosimilars: An ISPOR Special Interest Group Report. Value in Health 26:8, pages 1137-1144.
Crossref
Crossref
Yannick Vandenplas, Steven Simoens, Philippe Van Wilder, Arnold G. Vulto & Isabelle Huys. (2023) The impact of policy interventions to promote the uptake of biosimilar medicines in Belgium: a nationwide interrupted time series analysis. Health Research Policy and Systems 21:1.
Crossref
Crossref
Ahmad Nader Fasseeh, Baher Elezbawy, Kareem Ahmed El-Fass, Mary GamaI, Ahmed Seyam, Noha Hayek, Nagwan Abdel Rahman, Sohir Abdelhamid, Nader Fasseeh, Amr Shafik Saad, Ahmed Elagamy, Akram Mahmoud, Amal Samir Sedrak, Khaled Elshazly, Mariam Eldebeiky, Monica Talaat, Noura Maher Mohamed, Rania Ahmed Abdelaziz, Remonda Refaat, Shaimaa Akeel, Sherif Abaza & Zoltán Kaló. (2023) Maximizing the benefits of using biosimilars in Egypt. Journal of Pharmaceutical Policy and Practice 16:1.
Crossref
Crossref
Elif Car, Arnold G. Vulto, Mark Van Houdenhoven, Isabelle Huys & Steven Simoens. (2023) Biosimilar competition in European markets of TNF-alpha inhibitors: a comparative analysis of pricing, market share and utilization trends. Frontiers in Pharmacology 14.
Crossref
Crossref
Beate Bittner. (2023) Customer-centric product presentations for monoclonal antibodies. AAPS Open 9:1.
Crossref
Crossref
Serena Perna, Agnese Cangini, Roberto Marini, Maria Alessandra Guerrizio, Roberto Da Cas, Giuseppe Traversa & Francesco Trotta. (2022) Dynamics of price competition in Italian pharmaceutical off-patent market. Frontiers in Medicine 9.
Crossref
Crossref
Yannick Vandenplas, Steven Simoens, Florian Turk, Arnold G. Vulto & Isabelle Huys. (2022) Applications of Behavioral Economics to Pharmaceutical Policymaking: A Scoping Review with Implications for Best-Value Biological Medicines. Applied Health Economics and Health Policy 20:6, pages 803-817.
Crossref
Crossref
Saana V. Luukkanen, Hanna M. Tolonen, Marja Airaksinen & Laura S. M. Saarukka. (2022) The Price and Market Share Evolution of the Original Biologics and Their Biosimilars in Finland. BioDrugs 36:4, pages 537-547.
Crossref
Crossref
Sarfaraz K. Niazi. (2022) The Coming of Age of Biosimilars: A Personal Perspective. Biologics 2:2, pages 107-127.
Crossref
Crossref
Liese Barbier, Allary Mbuaki, Steven Simoens, Paul Declerck, Arnold G. Vulto & Isabelle Huys. (2022) Regulatory Information and Guidance on Biosimilars and Their Use Across Europe: A Call for Strengthened One Voice Messaging. Frontiers in Medicine 9.
Crossref
Crossref
Konstantin Tachkov, Zornitsa Mitkova, Petya Milushewa & Guenka Petrova. (2021) Biosimilar Insulins and Their Impact on Prices and Utilization of Insulins in Bulgaria. Healthcare 9:6, pages 697.
Crossref
Crossref
Liese Barbier, Steven Simoens, Caroline Soontjens, Barbara Claus, Arnold G. Vulto & Isabelle Huys. (2021) Off-Patent Biologicals and Biosimilars Tendering in Europe—A Proposal towards More Sustainable Practices. Pharmaceuticals 14:6, pages 499.
Crossref
Crossref
Jennifer FennaDaniel McCormackSophie KitchenDiana MartinsTara GomesMina Tadrous. (2021) Effect of listing strategies on utilization of antitumor necrosis factor biologics infliximab and etanercept: a cross-sectional analysis from Ontario, Canada. Journal of Managed Care & Specialty Pharmacy 27:4, pages 444-452.
Crossref
Crossref
Félix Lobo & Isabel Río-Álvarez. (2021) Barriers to Biosimilar Prescribing Incentives in the Context of Clinical Governance in Spain. Pharmaceuticals 14:3, pages 283.
Crossref
Crossref
Yannick Vandenplas, Steven Simoens, Philippe Van Wilder, Arnold G. Vulto & Isabelle Huys. (2021) Informing Patients about Biosimilar Medicines: The Role of European Patient Associations. Pharmaceuticals 14:2, pages 117.
Crossref
Crossref
Evelien Moorkens, Brian Godman, Isabelle Huys, Iris Hoxha, Admir Malaj, Simon Keuerleber, Silvia Stockinger, Sarah Mörtenhuber, Maria Dimitrova, Konstantin Tachkov, Luka Vončina, Vera Vlahović Palčevski, Gnosia Achniotou, Juraj Slabý, Leona Popelková, Kateřina Kohoutová, Dorthe Bartels, Ott Laius, Jaana E. Martikainen, Gisbert W. Selke, Vasileios Kourafalos, Einar Magnússon, Rannveig Einarsdóttir, Roisín Adams, Roberta Joppi, Eleonora Allocati, Arianit Jakupi, Anita Viksna, Ieva Greičiūtė-Kuprijanov, Patricia Vella Bonanno, Vincent Suttorp, Øyvind Melien, Robert Plisko, Ileana Mardare, Dmitry Meshkov, Tanja Novakovic, Jurij Fürst, Corinne Zara, Vanda Marković-Peković, Nataša Grubiša, Gustaf Befrits, Robert Puckett & Arnold G. Vulto. (2021) The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures. Frontiers in Pharmacology 11.
Crossref
Crossref
Gregory Reardon. 2020. Biologics, Biosimilars, and Biobetters. Biologics, Biosimilars, and Biobetters
195
212
.
Yujeong Kim, Hye-Young Kwon, Brian Godman, Evelien Moorkens, Steven Simoens & SeungJin Bae. (2020) Uptake of Biosimilar Infliximab in the UK, France, Japan, and Korea: Budget Savings or Market Expansion Across Countries?. Frontiers in Pharmacology 11.
Crossref
Crossref
Olga Barszczewska, Ralph Chami & Anna Piechota. (2020) Biosimilars in the French and Polish System: Chosen Aspects of Reimbursement and Access. Comparative Economic Research. Central and Eastern Europe 23:2, pages 103-115.
Crossref
Crossref
Kati Sarnola, Merja Merikoski, Johanna Jyrkkä & Katri Hämeen-Anttila. (2020) Physicians’ perceptions of the uptake of biosimilars: a systematic review. BMJ Open 10:5, pages e034183.
Crossref
Crossref
Evelien Moorkens, Steven Simoens, Per Troein, Paul Declerck, Arnold G. Vulto & Isabelle Huys. (2019) Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 1—Biosimilar and Originator Infliximab in the Hospital Setting. BioDrugs 33:3, pages 285-297.
Crossref
Crossref
Stanton R. Mehr & Richard A. Brook. (2019) Biosimilars in the USA: Will New Efforts to Spur Approvals and Access Spur Uptake and Cost Savings?. Pharmaceutical Medicine 33:1, pages 1-8.
Crossref
Crossref
J. O’Callaghan, S. P. Barry, M. Bermingham, J. M. Morris & B. T. Griffin. (2018) Regulation of biosimilar medicines and current perspectives on interchangeability and policy. European Journal of Clinical Pharmacology 75:1, pages 1-11.
Crossref
Crossref
Reyes Gámez-Belmonte, Cristina Hernández-Chirlaque, María Arredondo-Amador, Carlos J. Aranda, Raquel González, Olga Martínez-Augustin & Fermín Sánchez de Medina. (2018) Biosimilars: Concepts and controversies. Pharmacological Research 133, pages 251-264.
Crossref
Crossref
Kimberly Blackwell, Joseph Gligorov, Ira Jacobs & Chris Twelves. (2018) The Global Need for a Trastuzumab Biosimilar for Patients With HER2-Positive Breast Cancer. Clinical Breast Cancer 18:2, pages 95-113.
Crossref
Crossref
Rotraut Mössner. (2018) Biosimilars und Patientenversorgung. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 16:2, pages 133-134.
Crossref
Crossref
Rotraut Mössner. (2018) Biosimilars and patient care. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 16:2, pages 133-134.
Crossref
Crossref
Andras Inotai, Marcell Csanadi, Guenka Petrova, Maria Dimitrova, Tomasz Bochenek, Tomas Tesar, Kristina York, Leos Fuksa, Alexander Kostyuk, Laszlo Lorenzovici, Vitaly Omelyanovskiy, Katalin Egyed & Zoltan Kalo. (2018) Patient Access, Unmet Medical Need, Expected Benefits, and Concerns Related to the Utilisation of Biosimilars in Eastern European Countries: A Survey of Experts. BioMed Research International 2018, pages 1-9.
Crossref
Crossref
Evelien Moorkens, Arnold G. Vulto, Isabelle Huys, Pieter Dylst, Brian Godman, Simon Keuerleber, Barbara Claus, Maria Dimitrova, Guenka Petrova, Ljiljana Sović-Brkičić, Juraj Slabý, Robin Šebesta, Ott Laius, Allan Karr, Morgane Beck, Jaana E. Martikainen, Gisbert W. Selke, Susan Spillane, Laura McCullagh, Gianluca Trifirò, Patricia Vella Bonanno, Asbjørn Mack, Antra Fogele, Anita Viksna, Magdalena Władysiuk, Helder Mota-Filipe, Dmitry Meshkov, Marija Kalaba, Simona Mencej Bedrač, Jurij Fürst, Corrine Zara, Peter Skiöld, Einar Magnússon & Steven Simoens. (2017) Policies for biosimilar uptake in Europe: An overview. PLOS ONE 12:12, pages e0190147.
Crossref
Crossref